Topics covered: Valuations in small cap Biotech, Toll-like receptor (TLR) space, Therapeutic drug companies, Special Protocol Assessment (SPA) process, Reimbursement, Pipeline projects, Patent expirations, Oncology space, M&A expectations, Generic biologics, FDA environment
